ArticleAlzheimer's research & therapy2023
Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials.
Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Racial and Ethnic Reporting and Representation in US Alzheimer Clinical Trials: A Systematic Review.JAMA network open · 2026Pooled it
- Trial
- Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites.Alzheimer's research & therapy · 2025Trial
- A digital twin methodology using retrospective patient data for sample size reduction in Alzheimer's disease clinical trials.Alzheimer's research & therapy · 2026Article
- Enhanced monitoring of Alzheimer's disease brain atrophy using composite value ratios of volumes.Brain communications · 2026Article
- A digital twin methodology using real patient data for sample size reduction in Alzheimer's disease randomized controlled clinical trials.medRxiv : the preprint server for health sciences · 2025Article
- Development of a protocol complexity tool: a framework designed to stimulate discussion and simplify study design.BMC medical research methodology · 2025Article
- The utility of recruitment incentives in early Alzheimer's disease trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Portable Accessible MRI in Dementia Research: Ethical Considerations About Research Representation and Dementia-Friendly Technology.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2024Article
- A data-driven framework for biomarker discovery applied to optimizing modern clinical and preclinical trials on Alzheimer's disease.Brain communications · 2024Article
- Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade.The journal of prevention of Alzheimer's disease · 2024Article
- Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.Alzheimer's & dementia (New York, N. Y.)Article
- Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
- Effects of informant replacement in Alzheimer's disease clinical trials.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTimely accrual of a representative sample is a key factor in whether Alzheimer's disease (AD) clinical trials successfully answer the scientific questions under study. Studies in other fields have observed that, over time, recruitment to trials has become increasingly reliant on larger numbers of sites, with declines in the average per-site recruitment rate. Here, we examined the trends in recruitment over a 20-year period of NIH-funded AD clinical trials conducted by the Alzheimer's Disease Cooperative Study (ADCS), a temporally consistent network of sites devoted to interventional research.
methodsWe performed retrospective analyses of eleven ADCS randomized clinical trials. To examine the recruitment planning, we calculated the expected number of participants to be enrolled per site for each trial. To examine the actual trial recruitment rates, we quantified the number of participants enrolled per site per month.
resultsNo effects of time were observed on recruitment planning or overall recruitment rates across trials. No trial achieved an overall recruitment rate greater than one subject per site per month. We observed the fastest recruitment rates in trials with no competition and the slowest in trials that overlapped in time. The highest recruitment rates were consistently seen early within trials and declined over the course of studies.
conclusionsTrial recruitment projections should plan for fewer than one participant randomized per site per month and consider the number of other AD trials being conducted concurrently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.